NYSE:ANROPharmaceuticals
Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?
Alto Neuroscience (ANRO) has moved back into focus after expanding its ALTO-207 program with an additional Phase 3 trial for treatment-resistant depression, supported by fresh funding and independent mechanism-of-action data.
See our latest analysis for Alto Neuroscience.
The latest ALTO-207 update comes after a period of strong momentum for Alto Neuroscience, with a year-to-date share price return of 93.73% and a 1-year total shareholder return of about 9.2 times an initial investment. The...